AVDL AVADEL PHARMACEUTICALS PLC Product Launches 8-K Filing 2023 - FDA Approval of LUMRYZ for Narcolepsy Treatment Avadel Pharmaceuticals announced that the FDA has approved LUMRYZ, an extended-release formulation of sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy, and has granted Orphan Drug Exclusivity for seven years.Get access to all SEC 8-K filings of the AVADEL PHARMACEUTICALS PLC